HealthQuill Clinical trials
The USFDA approved Swiss-based Basilea Pharmaceutica International’s Zevtera injection for the treatment of staphylococcus aureus bloodstream infections and skin infections in adults and community-acquired bacterial pneumonia in patients three months to 18 years, and adults. 
Drugs Health Pharma

Swiss-based Basilea Pharmaceutical’s antimicrobial drug gets FDA nod 

HQ Team April 4, 2024: The USFDA approved Swiss-based Basilea Pharmaceutica International’s Zevtera injection for the treatment of staphylococcus aureus bloodstream infections and.

Read More
Overuse of antibiotics
Drugs Health Medical

DoxyPEP can work as morning after pill for STIs

HQ Team April 1, 2024: Preventing the spread of sexually transmitted infections (STIs) might soon be as simple as taking a couple of.

Read More
Eli Lilly's Omvah gains FDA approval for treating Crohn's disease
Drugs Health Pharma

Bristol’s oral drug to treat Crohn’s disease fails remission test

HQ Team March 29, 2024: Bristol Myers Squibb’s final stage clinical trials for its Zeposia oral drug, to treat moderate to severe Crohn’s.

Read More
US-based biotechnology company Viking Therapeutics Inc., reported “positive” results from its early-stage weight-loss oral drug and the pill showed mild to moderate side effects.
Drugs Health Pharma

Viking Therapeutics’ weight-loss drug shows ‘positive’ results in early trials

US-based biotechnology company Viking Therapeutics Inc., reported “positive” results from its early-stage weight-loss oral drug and the pill showed mild to moderate side.

Read More
Novo Nordisk, one of the world’s most valuable companies, will acquire Germany-based Cardior Pharmaceuticals, a firm that specialises in heart diseases, for up to 1.03 billion euros ($1.1 billion).
Drugs Health Pharma

Novo to buy Cardior for $1.1b to expand cardiovascular segment

HQ Team March 25, 2024: Novo Nordisk, one of the world’s most valuable companies, will acquire Germany-based Cardior Pharmaceuticals, a firm that specialises.

Read More
Bayer AG, a German pharmaceutical major, will seek regulatory approval for its menopausal drug after the final trials proved to reduce hot flashes.
Drugs Health Pharma

Bayer’s menopausal drug lowers hot flashes, to seek regulatory nod

HQ Team March 19, 2024: Bayer AG, a German pharmaceutical major, will seek regulatory approval for its menopausal drug after the final trials.

Read More
Pfizer Inc., announced that a late-stage study on its Adcetris drug, for treating the most common lymphoma, yielded positive results and improved overall survival rates.
Drugs Health Pharma

Pfizer says trials on lymphoma drug ‘positive,’ extends life of patients 

HQ Team March 12, 2024: Pfizer Inc., announced that a late-stage study on its Adcetris drug, for treating the most common lymphoma, yielded.

Read More
Novo Nordisk’s diabetes drug Ozempic delayed the progression of kidney disease and cardiovascular and kidney death in 24% of people involved in trials, the company announced.
Drugs Health Pharma

Novo Nordisk says Ozempic reduces kidney disease progression 

HQ Team March 6, 2024: Novo Nordisk’s diabetes drug Ozempic delayed the progression of kidney disease and cardiovascular and kidney deaths in 24%.

Read More
US-based Akero Therapeutics, Inc., announced its mid-trial of a drug to treat fatty liver disease met its primary goals of efficacy and safety in patients, according to a company statement.
Drugs Health Pharma

Akero Therapeutics says mid-stage trials on drug for fatty liver disease positive

HQ Team March 4, 2024: US-based Akero Therapeutics, Inc., announced its mid-trial of a drug to treat fatty liver disease met its primary.

Read More
An asthma drug, omalizumab, can “significantly” reduce the risk of allergic reactions caused by multiple foods among children and adults in case of accidental exposure, according to a study funded by the US medical research agency.
Drugs Health Pharma

Omalizumab or Xolair can lower risk of food allergies in kids, adults: NIH

HQ Team February 26, 2024: An asthma drug, omalizumab, can “significantly” reduce the risk of allergic reactions caused by multiple foods among children.

Read More